Excretion

Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics: Featuring Bluebird Bio, Atara, Perseo Pharma & More - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Molecule, Regenerative medicine, Nanoparticle, Disease management, Tissue engineering, Drug discovery, Wellness, Infection, Biomarker, Synthetic biology, Drug design, Pain, Health, Cancer, Excretion, Nanomedicine, Genetic engineering, Present value of growth opportunities, Ministry of Health & Wellness, Inflammation, Nanotechnology, Control, Innovation, Metabolism, Pharmaceutical industry

The "Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics" report has been added to ResearchAndMarkets.com's offering.
  • This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on advanced autologous and allogeneic cell therapies for cancers.
  • It also covers developments in ADCs and small molecules for multiple cancers.
  • Synthetic biology innovations around low cost gene synthesis and deployment of gene circuits have been featured as well.

Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Trial of the century, IP, Engineering, ATM, Patent, Safety, Disease, Growth, Plasma, MDD, NYSE American, PK, News, Drug development, Health Canada, Research, Neuropharmacology, Nature, Excretion, Intellectual property, EDGAR, COVID-19, Business, Psilocybin, Metabolism, Psychedelic drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, Inc., United Kingdom, Therapy, DMT, Pharmacokinetics, Cerebral cortex, Hemodynamics, Drug discovery, Food, NEO, Knowledge, Catalog, Calendar, Risk, Anxiety, NYSE, PD, USD, Patient, Renewable energy, Pharmaceutical industry, Risk management, Absorption, Kernel

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.
  • Depending on market conditions, this will allow Cybin to access additional cash for growth opportunities and working capital.
  • Recent Business and Pipeline Highlights:
    Reported progress update on CYB004-E Phase 1 trial.
  • Collectively, Cybin now has access to more than 35 patents and applications through a combination of internal filings and licensing arrangements.

Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Monday, August 8, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, U.S. Securities and Exchange Commission, Risk, NEO, Trial of the century, Patent, Inc., Knowledge, Research, Patient, News, Food, Disease, MDD, Industry, Flow, DMT, Safety, Kernel, Nature, Metabolism, Pharmacokinetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuropharmacology, United Kingdom, Forward-looking statement, Growth, EDGAR, Engineering, Therapy, COVID-19, Acquisition, Excretion, Anxiety, Drug development, Health Canada, Time, United States Patent and Trademark Office, Organization, FDA, NYSE, IP, Lists of diseases, Psilocybin, Plasma, Calendar, Company, View, Central nervous system, NYSE American, World Intellectual Property Organization, Pharmaceutical industry, Online gambling, Risk management, Absorption

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights.
  • Recent Business and Pipeline Highlights:
    Initiated enrollment for its first-in-human Phase 1/2a trial of CYB003 in major depressive disorder (MDD).
  • Based on preclinical data, CYB003 achieved less variability in plasma levels, faster onset of action, and shorter duration of effect.
  • If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

Outlook on the Commercial Vehicle Urea Tank Global Market to 2030 - Key Trends, Growth Opportunities and Forecast Scenarios - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Automotive, Other Automotive, Physical sciences, Fertilizers, Household chemicals, Nitrogen cycle, Natural sciences, Chemistry, Excretion, Lymph fluid, Urea, Market research

Commercial Vehicle Urea Tank Market Trends, Growth Opportunities, and Forecast Scenarios to 2030

Key Points: 
  • Commercial Vehicle Urea Tank Market Trends, Growth Opportunities, and Forecast Scenarios to 2030
    Lockdowns across the globe in 2020 and continuing restrictions in 2021 disrupted the Commercial Vehicle Urea Tank supply chain posing challenges for manufacturers in the Commercial Vehicle Urea Tank industry.
  • The Commercial Vehicle Urea Tank research report portrays the latest trends shaping the Commercial Vehicle Urea Tank industry along with key demand drivers and potential challenges anticipated for the market during the outlook period.
  • Global Commercial Vehicle Urea Tank Market Introduction, 2021
    5.1 Commercial Vehicle Urea Tank Industry Attractiveness Index, 2021
    6.
  • Latin America Commercial Vehicle Urea Tank Market Drivers, Challenges, and Growth Prospects
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005068/en/

Commercial Vehicle Urea Tank Market | 2.8% YOY Growth Expected in 2021 | Technavio

Retrieved on: 
Monday, September 6, 2021
Fertilizers, Physical sciences, Nitrogen cycle, Natural sciences, Household chemicals, Chemistry, Excretion, Lymph fluid, Urea, Marketplace

Buy our market report now to gain access to detailed analysis on the commercial vehicle urea tank market: https://www.technavio.com/talk-to-us?report=IRTNTR44357

Key Points: 
  • Buy our market report now to gain access to detailed analysis on the commercial vehicle urea tank market: https://www.technavio.com/talk-to-us?report=IRTNTR44357
    Commercial Vehicle Urea Tank Market 2021-2025: Vendor Analysis and Scope
    Some of the major vendors of the commercial vehicle urea tank market in the auto parts & equipment industry include ACGB France, Centro Inc., Cummins Inc., Dongguan Zhengyang Electronic Mechanical Ltd., Elkamet Kunststofftechnik GmbH, Gemini Group Inc., Hitachi Zosen Corp., Myers Industries Inc., Rochling SE and Co. KG, and Salzburger Aluminium AG.
  • To help businesses improve their market position, Technavio's report provides a detailed analysis of around 25 vendors operating in the market.
  • The report also covers the following areas:
    The commercial vehicle urea tank market is concentrated, and the degree of concentrationwill accelerate.
  • Backed with competitive intelligence and benchmarking, our research reporton the commercial vehicle urea tank market is designed to provide entry support, customer profile, & M&As as well as go-to-market strategy support.

New Data Suggest Men with Urinary Symptoms Often Anticipate Bathroom Needs and Avoid Events and Activities They Enjoy

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Clinical medicine, Medicine, Urology, Urine, Excretion, Partial squatting position, Urination, Benign prostatic hyperplasia, Urinary incontinence

The survey included approximately 1,000 men in the United States, 45 years and older, who have experienced at least one of these urinary symptoms.

Key Points: 
  • The survey included approximately 1,000 men in the United States, 45 years and older, who have experienced at least one of these urinary symptoms.
  • Nearly half (45.49%) of all men surveyed reported they have avoided events or activities they enjoy because of their urinary symptoms.
  • When they do attend an event or perform an activity, a significant number of men surveyed make plans or take action to accommodate their bathroom needs.
  • Many men with urinary problems, including BPH patients, experience frequent nighttime waking to use the bathroom to urinate.

Waterless Celebrates 30th Anniversary

Retrieved on: 
Tuesday, May 4, 2021
Other Manufacturing, Environment, Commercial Building & Real Estate, Construction & Property, Building Systems, Manufacturing, Other Natural Resources, Architecture, Other Construction & Property, Natural Resources, Toilets, Urine, Excretion, Urinal, Public health, Hygiene, Female urinal

Nobody even knew what a waterless urinal was.

Key Points: 
  • Nobody even knew what a waterless urinal was.
  • "This makes waterless urinals the perfect fixture for the restroom of the future.
  • Based in Vista, Ca., the company was started in 1991 and is the oldest manufacturer of waterless urinals in North America.
  • The company manufactures a full line of waterless no-flush urinals, cleaning liquids, and cost saving restroom accessories.

Salimetrics Online Workshops -- Translating the Best Guide, "Foundations of Interdisciplinary Saliva Research & Applications", into easy steps for research applications

Retrieved on: 
Wednesday, March 31, 2021
Excretion, Saliva

Salimetrics Online Bioscience Workshops expand on "Foundations of Interdisciplinary Saliva Research and Applications" by translating key points into practical steps.

Key Points: 
  • Salimetrics Online Bioscience Workshops expand on "Foundations of Interdisciplinary Saliva Research and Applications" by translating key points into practical steps.
  • Salimetrics workshops present attendees with technical advice on saliva collection, handling, transport and storage, and also includes important considerations that researchers should be aware of when designing a study.
  • Researchers can confidently design studies around high-impact concepts, based on compliance with and application of the latest knowledge.
  • "Questions are now being answered with saliva as the sample type that could not have been answered using traditional biological specimens," says Dr. Gaitonde.

Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Health sciences, Biology, Digestive system, Elimination, Excretion, Metabolism, Pharmacokinetics, Pharmacy, Epidermal growth factor receptor, EGFR

These data support our Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with G542X alleles.

Key Points: 
  • These data support our Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with G542X alleles.
  • This study was designed to define the relationship of eGFR and drug exposure and urinary clearance in patients with renal impairment.
  • The results demonstrated that ELX-02 was well tolerated by patients with renal insufficiency and nephropathic cystinosis patients.
  • Across increasing degrees of renal insufficiency with reduced clearance, ELX-02 pharmacokinetics demonstrated increased exposure and prolonged renal elimination proportional to eGFR.

North American Adult Diapers Market Forecast to 2027 - North American Market is Forecast to Grow at a CAGR of 12.8% from 2019 to 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021
Medical Supplies, Health, Clothing, Incontinence, Diapers, Undergarments, Excretion, Medical specialties, Adult diaper, Urinary incontinence, Fecal incontinence, Incontinence underwear, Diaper need

The North America adult diapers market was valued at US$ 2,261.50 million in 2018 and is projected to reach US$ 6,666.22 million by 2027; it is expected to grow at a CAGR of 12.8% from 2019 to 2027.

Key Points: 
  • The North America adult diapers market was valued at US$ 2,261.50 million in 2018 and is projected to reach US$ 6,666.22 million by 2027; it is expected to grow at a CAGR of 12.8% from 2019 to 2027.
  • The adult diapers are commonly used by elderly individuals experiencing conditions such as dementia, extreme bowel looseness, versatility debilitation, and incontinence.
  • Based on product type, the North America adult diapers market is segmented into pant type, pad type, tape type, others.
  • The rising incidence of urinary incontinence among adults is contributing to the growth of pant type adult diapers market in North America.